ICU Medical (NASDAQ:ICUI) Updates FY24 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $5.40-5.70 for the period, compared to the consensus earnings per share estimate of $5.24.

Analysts Set New Price Targets

Several equities research analysts recently commented on ICUI shares. Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Raymond James boosted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. KeyCorp raised their target price on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $170.25.

ICU Medical Stock Down 0.1 %

ICUI traded down $0.26 on Tuesday, reaching $178.01. The company’s stock had a trading volume of 267,138 shares, compared to its average volume of 273,285. ICU Medical has a fifty-two week low of $79.85 and a fifty-two week high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The stock has a 50 day moving average of $175.56 and a two-hundred day moving average of $141.16. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of -61.05 and a beta of 0.66.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,502 shares of company stock valued at $8,445,976 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.